CHICAGO -- Omitting lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy did not compromise ...

Please provide your email address to receive an email when new articles are posted on . Extended lymphadenectomy did not improve outcomes in localized muscle-invasive bladder cancer vs. standard ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer. The addition of retroperitoneal ...

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR ...

Fluorescence-guided lymphadenectomy after neoadjuvant chemotherapy was linked to improved survival in gastric cancer. It was also significantly associated with more retrieved lymph nodes. The 3-year ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

Extended lymphadenectomy did not improve disease-free or overall survival compared to standard lymphadenectomy in muscle-invasive bladder cancer patients. Higher perioperative morbidity and mortality ...

An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because ...

A total of 523 patients were randomized between July 1995 and April 2001. Postoperative complications were reported in 24.5% of all patients. Although the morbidity for the extended surgery group ...